Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
- Post author:admin
- Post published:July 14, 2026
- Post category:uncategorized